National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "5 Categories of Scientific Evidence--Animal Data." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
157
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

harm, strength of evidence, and dose administered to animals factor into assessing animal data, along with general guidelines for integrating these factors. Animal data that raise a higher level of concern warrant immediate attention to evaluate the potential of the ingredient to cause harm. For data classified as lower to moderate concern, it is important to consider whether other animal data or other types of data (e.g., human data, in vitro data, or data on related substances) add to the level of concern.

POWER AND RELEVANCE OF ANIMAL DATA

Animal testing provides invaluable information about the potential for ingested substances to cause harm in humans. Studies in animals are regularly used as an important step in attempting to predict untoward effects of substances in humans (see, for example, the Food and Drug Administration’s [FDA’s] Redbook [OFAS, 2001, 2003] or guidance documents for new drugs [CDER, 2002]).

Animal studies are powerful because controlled studies can be conducted to predict effects that might not be detected from customary use by humans until they result in overt harmful effects. Animal studies are especially useful in detecting effects of chronic exposures and effects on reproductive and developmental processes because epidemiological methods of studying humans are especially problematic in these areas. The ability to administer agents to animals during their entire lifespan, if necessary, enables scientists to ascertain the potential toxic effects that may arise from long-term (chronic) exposure. Animal studies thus serve as important hypothesis generators and may be sufficient to indicate potentially unreasonable risk to human health, which justifies their use in evaluating the risks dietary supplement ingredients may pose to humans.

In general, adverse effects observed in well-designed and well-conducted animal studies should be treated as if they would occur in at least some members of the human population, assuming humans receive a sufficiently high dose. With some notable and important exceptions, the biological factors affecting the capacity of chemical substances to cause toxicity are broadly similar across mammalian species. Unless there is scientific evidence that raises significant doubt regarding the relevance of specific toxicity findings to humans, it is prudent and scientifically appropriate to consider animal studies relevant in evaluating potential human toxicity, especially in the many cases of dietary supplement ingredients where sufficient human data are not available. Similar positions on the relevance of animal data to human health have been supported by other committees of the National Academies, as well as by other organizations in the United States and internationally (NRC, 1994, 2001; NTP, 2002; WHO, 1999).

Page
157
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)